The story has been updated to include comments from the company's conference call.
NEW YORK – Bio-Techne said on Tuesday morning that its total fiscal fourth quarter sales declined 8 percent year over year while its Diagnostics and Genomics segment was essentially flat.
For the three months ended June 30, the Minneapolis-based company reported sales of $175.8 million, down from $191.7 million a year ago. It beat the consensus Wall Street estimate of $163.9 million. Organically, sales in Q4 2020 also declined 8 percent.